Form 4: Compass Therapeutics CEO Granted 1.5 Million Stock Options

Compass Therapeutics CEO Thomas J. Schuetz was granted 1,500,000 stock options on February 11, 2025, according to a recent SEC filing.

Summary

• Thomas J. Schuetz, CEO of Compass Therapeutics, was granted 1,500,000 stock options on February 11, 2025.
• The options have an exercise price of $3.65.
• The options vest in 48 substantially equal monthly installments starting March 11, 2025.
• The options expire on February 11, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The grant of stock options is a standard practice, and the details provided are factual. It's neither overwhelmingly positive nor negative.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Risks

• The vesting schedule could incentivize short-term decision-making to meet vesting milestones.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant (1,500,000 options) would need to be compared to grants given to CEOs of similarly sized biotech companies to determine if it is above or below industry averages.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the CEO's interests with increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates